Glucokinase Pipeline Review, H2 2019
Summary
Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the betacell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulinsensitive determinant of hepatic glucose usage.
Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Diabetes, Obesity and Type 1 Diabetes Juvenile Diabetes.
The latest report Glucokinase Pipeline Review, H2 2019, outlays comprehensive information on the Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Scope
The report provides a snapshot of the global therapeutic landscape for Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2
The report reviews Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics and enlists all their major and minor projects
The report assesses Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope